Redenlab joins global Friedreich Ataxia collaboration

Redenlab contributes to TRACK-FA, a global, multi-stakeholder, consortium launched to study neuroimaging biomarkers for Friedreich Ataxia.

Redenlab has entered into a 5 year collaboration with investigators from North and South America, Australia and Europe to investigate the underlying neural mechanisms of Friedreich ataxia. The study is supported by the Friedreich’s Ataxia Research Alliance (FARA) and pharmaceutical industry partners.

Redenlab are providing speech testing and analytics for the study.

Friedreich ataxia is a multisystem neurodegenerative disorder and the most common of the hereditary ataxia syndromes. It is caused by a triplet repeat expansion in the FXN gene, which leads to reduced frataxin, a mitochondrial protein important for iron metabolism. Symptoms typically present at 10-15 years of age but can be earlier or considerably later, and patients are usually wheelchair dependent within 10–15 years of disease onset. Other deficits include dysarthria and dysphagia, progressive limb and gait ataxia, optic and auditory neuropathy, scoliosis, and cardiomyopathy.

Learn more here.  

Related Post

  • Posted on 28 November, 2021
    Dr Garcia joins the Redenlab science team to drive its language analytics pipeline for cognitive-linguistic disorders like fronto-temporal dementia. Adolfo...
    • Posted on 21 July, 2021
      The ARC Training Centre for Optimal Ageing aims to address issues identified by older adults as essential for quality of...
      • Posted on 31 May, 2021
        Redenlab is supporting a new speech focussed consortium for ataxia. SpeechATAXIA is a multi-language, multi-national, multi-ataxia study measuring communication change....